| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 50.2 | 44.2 |
| Gross profit | 23.8 | 21.3 |
| Profit before tax | -10.7 | -6.5 |
| Net income | -10.9 | -6.9 |
| EPS (diluted, $ a share) | $-0.25 | $-0.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +13.5% |
|---|---|
| Gross margin | 47.5% |
| Operating margin | -17.5% |
10-Q filed with the SEC, NASDAQ: CYRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cryoport, Inc.: key numbers
- Share price
- $19.80Close, Nov 16
- Market cap
- $1B
- Shares outstanding
- 50.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cryoport, Inc.
All →Cryoport CSO Mark W. Sawicki Sells $199K of Stock
Mark W. Sawicki, CSO, sold 10,000 shares of Cryoport, Inc. at $19.93 a share, worth $199K in total on Nov 10, 2026. Shares held after the trade: 92,356 (-9.8%).
- Value
- $199K
- Shares
- 10,000
- Price
- $19.93
- Role
- CSO
- Holding change
- -9.8%
- Trade date
- Nov 10, 2026
Cryoport Insider Daniel M. Hancock Sells $1.5M of Stock
Daniel M. Hancock sold 74,379 shares of Cryoport, Inc. at $20.21 a share, worth $1.5M in total on Nov 9, 2026. Shares held after the trade: 69,052 (-51.9%).
- Value
- $1.5M
- Shares
- 74,379
- Price
- $20.21
- Holding change
- -51.9%
- Trade date
- Nov 9, 2026
Cryoport Financial Results
Cryoport reported Q3 2026 revenue of $50.2 million, a 14% increase year-over-year, driven by 20% growth in commercial Cell and Gene Therapy revenue. The company achieved positive adjusted EBITDA of $1.1 million and raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.
- Term
- Q3 2026
“Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions.”
Jerrell Shelton, CEO of Cryoport
“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million.”
Jerrell Shelton, CEO of Cryoport